CS
MDGL icon

Candriam SCA’s Madrigal Pharmaceuticals MDGL Stock Holding History

Candriam SCA’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.7M Sell
72,121
-12,827
-15% -$6.57M 0.17% 123
2026
Q1 		$44.5M Buy
84,948
+21,042
+33% +$10.1M 0.23% 97
2025
Q4 		$37.2M Buy
63,906
+13,941
+28% +$7.12M 0.19% 124
2025
Q3 		$22.9M Hold
49,965
– – 0.12% 164
2025
Q2 		$15.1M Buy
49,965
+28,593
+134% +$8.52M 0.09% 199
2025
Q1 		$7.08M Buy
+21,372
New +$7.02M 0.04% 275
2024
Q2 		– Sell
-18,000
Closed -$4.81M – 709
2024
Q1 		$4.81M Sell
18,000
-9,000
-33% -$2.12M 0.03% 350
2023
Q4 		$6.25M Sell
27,000
-2,000
-7% -$350K 0.04% 309
2023
Q3 		$4.24M Hold
29,000
– – 0.03% 326
2023
Q2 		$6.7M Buy
+29,000
New +$7.85M 0.05% 296
2021
Q2 		– Sell
-31,722
Closed -$3.39M – 924
2021
Q1 		$3.39M Hold
31,722
– – 0.03% 437
2020
Q4 		$3.53M Sell
31,722
-62,862
-66% -$7.68M 0.03% 448
2020
Q3 		$11.2M Sell
94,584
-8,000
-8% -$869K 0.11% 211
2020
Q2 		$11.6M Buy
102,584
+61,634
+151% +$6.06M 0.12% 195
2020
Q1 		$3.65M Hold
40,950
– – 0.04% 423
2019
Q4 		$3.73M Sell
40,950
-500
-1% -$48.5K 0.04% 437
2019
Q3 		$3.57M Hold
41,450
– – 0.05% 386
2019
Q2 		$4.33M Hold
41,450
– – 0.05% 363
2019
Q1 		$5.19M Buy
41,450
+10,000
+32% +$1.24M 0.07% 315
2018
Q4 		$3.54M Buy
31,450
+17,500
+125% +$2.71M 0.05% 347
2018
Q3 		$2.99M Buy
13,950
+4,550
+48% +$1.14M 0.04% 416
2018
Q2 		$2.63M Buy
+9,400
New +$1.65M 0.04% 426

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's MDGL Position: Q2 2026 in Review

Candriam SCA reduced its Madrigal Pharmaceuticals (MDGL) stake by 15% in Q2 2026, selling an estimated $6.57M and leaving 72,121 shares worth $38.7M. The position accounts for 0.17% of the portfolio, ranked #123.

Candriam SCA first reported a position in MDGL in Q2 2018 and has held it in 22 quarters since. The position peaked at $44.5M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Candriam SCA held 72,121 shares of Madrigal Pharmaceuticals worth $38.7M as of Q2 2026.
  • Candriam SCA sold 12,827 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.57M.
  • Madrigal Pharmaceuticals made up 0.17% of Candriam SCA's portfolio in Q2 2026, its #123 holding.
  • Candriam SCA first reported a position in Madrigal Pharmaceuticals in Q2 2018 and has held it in 22 quarters since.
  • Candriam SCA's Madrigal Pharmaceuticals position peaked at $44.5M in Q1 2026.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.